Venous thromboembolism and cancer.
Bergqvist
David
D
Uppsala University Hospital, Department of Surgical Sciences, Uppsala, Sweden.
Caprini
Joseph A
JA
Dotsenko
Olena
O
Kakkar
Ajay K
AK
Mishra
Rajesh G
RG
Wakefield
Thomas W
TW
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D019983:Guideline Adherence; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008562:Membrane Glycoproteins; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology / Q000601:surgery; D019007:P-Selectin / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D011655:Pulmonary Embolism / Q000453:epidemiology* / Q000401:mortality / Q000503:physiopathology; D018570:Risk Assessment; D013925:Thromboplastin / Q000502:physiology; D020246:Venous Thrombosis / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology / Q000517:prevention & control
D020533:Angiogenesis Inhibitors; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D008562:Membrane Glycoproteins; D019007:P-Selectin; C084882:P-selectin ligand protein; D013925:Thromboplastin